Soligenix's Clinical Results From HyBryte Compatibility Study For Cutaneous T-Cell Lymphoma Published In JEADV Clinical Practice
Portfolio Pulse from Benzinga Newsdesk
Soligenix's clinical results from the HyBryte compatibility study for cutaneous T-cell lymphoma have been published in JEADV Clinical Practice. The study showed a 22% treatment response after 8 weeks, reinforcing previous Phase 3 trial results.
May 16, 2024 | 11:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Soligenix's HyBryte treatment for cutaneous T-cell lymphoma showed a 22% response rate in a recent study, reinforcing previous Phase 3 results. This could positively impact the stock as it confirms the efficacy of their treatment.
The publication of positive clinical results in a reputable journal reinforces the efficacy of Soligenix's HyBryte treatment, which is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100